It is worth noting that the use of rapamycin to inhibit mTOR, the key factor by which Ghrelin regulates liver activity, in the treatment of liver diseases might seriously hinder the proliferation of liver cells, and mTOR-independent intervention in Ghrelin signaling pathways may have better research value in the treatment of liver diseases. The gene discussed is MTOR; the disease is liver disorder.